Equillium, a biotech company developing treatments for severe autoimmune diseases, saw its stock price plummet almost 38% on Thursday, October 31. The sharp drop followed news that Japan’s Ono Pharmaceutical had opted not to exercise its option to purchase rights to Equillium’s experimental drug for organ transplant rejection. In early…